Conceptual aspects of combining rituximab and Campath-IH in the treatment of chronic lymphocytic leukemiaNABHAN, Chadi; ROSEN, Steven T.Seminars in oncology. 2002, Vol 29, Num 1, pp 75-80, issn 0093-7754, SUP2Article

Recent advances and future directions using monoclonal antibodies for B-cell malignanciesROSEN, Steven T.Seminars in oncology. 1999, Vol 26, Num 5, issn 0093-7754, 125 p., SUP14Conference Proceedings

Proceedings of the Northwestern University Medical School. Second Annual Oncology Consensus Conference: Recent Advances and New Therapeutic Directions for Hematologic MalignanciesROSEN, Steven T.Seminars in oncology. 2000, Vol 27, Num 6, issn 0093-7754, 111 p., SUP12Conference Proceedings

Treatment of aggressive non-Hodgkin's lymphomaCOIFFIER, B.Seminars in oncology. 1999, Vol 26, Num 5, pp 12-20, issn 0093-7754, SUP14Conference Paper

Chemotherapy sensitization by rituximab : Experimental and clinical evidenceWILSON, Wyndham H.Seminars in oncology. 2000, Vol 27, Num 6, pp 30-36, issn 0093-7754, SUP12Conference Paper

CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphomaCZUCZMAN, M. S.Seminars in oncology. 1999, Vol 26, Num 5, pp 88-96, issn 0093-7754, SUP14Conference Paper

Radiolabeled antibody therapy of B-cell lymphomasPRESS, O. W.Seminars in oncology. 1999, Vol 26, Num 5, pp 58-65, issn 0093-7754, SUP14Conference Paper

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma : Interim follow-up of a multicenter phase ii trialHAINSWORTH, John D.Seminars in oncology. 2002, Vol 29, Num 1, pp 25-29, issn 0093-7754, SUP2Article

Advances in classification and therapy of indolent B-cell malignanciesKIPPS, Thomas J.Seminars in oncology. 2002, Vol 29, Num 1, pp 98-104, issn 0093-7754, SUP2Article

High-dose rituximab therapy in chronic lymphocytic leukemiaKEATING, Michael; O'BRIEN, Susan.Seminars in oncology. 2000, Vol 27, Num 6, pp 86-90, issn 0093-7754, SUP12Conference Paper

The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphomaWITZIG, Thomas E.Seminars in oncology. 2000, Vol 27, Num 6, pp 74-78, issn 0093-7754, SUP12Conference Paper

Overview of posttransplant B-cell lymphoproliferative disordersSWINNEN, L. J.Seminars in oncology. 1999, Vol 26, Num 5, pp 21-25, issn 0093-7754, SUP14Conference Paper

Overview of idiopathic thrombocytopenic purpura : New approach to refractory patientsBUSSEL, James B.Seminars in oncology. 2000, Vol 27, Num 6, pp 91-98, issn 0093-7754, SUP12Conference Paper

Rituximab : An insider's historical perspectiveGRILLO-LOPEZ, Antonio J.Seminars in oncology. 2000, Vol 27, Num 6, pp 9-16, issn 0093-7754, SUP12Conference Paper

Rituximab as first-line systemic therapy for patients with low-grade lymphomaHAINSWORTH, John D.Seminars in oncology. 2000, Vol 27, Num 6, pp 25-29, issn 0093-7754, SUP12Conference Paper

Current treatment of follicular low-grade lymphomasPETERSON, B. A.Seminars in oncology. 1999, Vol 26, Num 5, pp 2-11, issn 0093-7754, SUP14Conference Paper

Quality of life and treatment value in the management of hematologic malignanciesCELLA, D; WEBSTER, K. A.Seminars in oncology. 1999, Vol 26, Num 5, pp 34-42, issn 0093-7754, SUP14Conference Paper

The role of CAMPATH-I antibodies in the treatment of lymphoid malignanciesDYER, M. J. S.Seminars in oncology. 1999, Vol 26, Num 5, pp 52-57, issn 0093-7754, SUP14Conference Paper

Molecular diagnostics in follicular non-Hodgkin's lymphoma : A reviewBORDELEAU, Louise; BERINSTEIN, Neil L.Seminars in oncology. 2000, Vol 27, Num 6, pp 42-52, issn 0093-7754, SUP12Conference Paper

Inhibition of Glycogen Synthase Kinase-3 Increases the Cytotoxicity of EnzastaurinROVEDO, Mark A; KRETT, Nancy L; ROSEN, Steven T et al.Journal of investigative dermatology. 2011, Vol 131, Num 7, pp 1442-1449, issn 0022-202X, 8 p.Article

Mechanisms of glucocorticoid-mediated apoptosis in hematological malignanciesGREENSTEIN, Stephanie; GHIAS, Kulsoom; KRETT, Nancy L et al.Clinical cancer research. 2002, Vol 8, Num 6, pp 1681-1694, issn 1078-0432Article

Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphomaWARREN, Thomas L; WEINER, George J.Seminars in oncology. 2002, Vol 29, Num 1, pp 93-97, issn 0093-7754, SUP2Article

Emerging information on the use of rituximab in chronic lymphocytic leukemiaKEATING, Michael J; O'BRIEN, Susan; ALBITAR, Maher et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 70-74, issn 0093-7754, SUP2Article

The use of rituximab in the treatment of malignant and nonmalignant plasma cell disordersTREON, Steven P; ANDERSON, Kenneth C.Seminars in oncology. 2000, Vol 27, Num 6, pp 79-85, issn 0093-7754, SUP12Conference Paper

Primary cutaneous lymphomas : a review with current treatment optionsQUERFELD, Christiane; GUITART, Joan; KUZEL, Timothy M et al.Blood reviews. 2003, Vol 17, Num 3, pp 131-142, issn 0268-960X, 12 p.Article